Skip to main content
. 2018 Mar 14;26(5):1299–1312. doi: 10.1016/j.ymthe.2018.03.009

Figure 5.

Figure 5

miR-223-3p Inhibits Osteosarcoma Initiation and Metastasis

(A and B) Stable 143B cells overexpressing miR-223-3p and miR-223-3p and CDH6 were injected into nude mice (A). At the indicated times, tumors were measured with Vernier calipers (mean ± SD; n = 6) (B). (C) Immunoblot analysis of representative excised tumors in (A) is shown. (D) Kaplan-Meier survival curves and log rank tests were performed to evaluate the role of miR-223-3p and CDH6 treatments in vivo. (E and F) Bioluminescence imaging of metastasis of osteosarcoma cells in non-obese diabetic (NOD)-severe combined immunodeficiency (SCID) mice at 28 days after intravenous injection of cells infected with PCDH-control, PCDH-miR-223-3p, or PCDH-miR-223-3p and CDH6 via the lateral tail vein is shown (E). The luminescence signal is represented by an overlaid false-color image with the signal intensity indicated by the scale (F). (G and H) Representative metastatic foci of lungs were subjected to anatomical (G) and histological (H) analyses. The data are shown as the mean ± SD (n = 6). *p < 0.05; **p < 0.01.